- Home
- ENLV vs TENX Comparison
ENLV vs TENX Comparison
Compare ENLV & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENLV
- TENX
- Stock Information
- Founded
- ENLV 2005
- TENX 1967
- Country
- ENLV Israel
- TENX United States
- Employees
- ENLV N/A
- TENX N/A
- Industry
- ENLV Biotechnology: Pharmaceutical Preparations
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- ENLV Health Care
- TENX Health Care
- Exchange
- ENLV Nasdaq
- TENX Nasdaq
- Market Cap
- ENLV 20.7M
- TENX 21.7M
- IPO Year
- ENLV 1995
- TENX N/A
- Fundamental
- Price
- ENLV $1.01
- TENX $6.30
- Analyst Decision
- ENLV Strong Buy
- TENX Strong Buy
- Analyst Count
- ENLV 2
- TENX 3
- Target Price
- ENLV $10.00
- TENX $16.00
- AVG Volume (30 Days)
- ENLV 146.1K
- TENX 20.7K
- Earning Date
- ENLV 04-11-2025
- TENX 05-13-2025
- Dividend Yield
- ENLV N/A
- TENX N/A
- EPS Growth
- ENLV N/A
- TENX N/A
- EPS
- ENLV N/A
- TENX N/A
- Revenue
- ENLV N/A
- TENX N/A
- Revenue This Year
- ENLV N/A
- TENX N/A
- Revenue Next Year
- ENLV N/A
- TENX N/A
- P/E Ratio
- ENLV N/A
- TENX N/A
- Revenue Growth
- ENLV N/A
- TENX N/A
- 52 Week Low
- ENLV $0.81
- TENX $2.77
- 52 Week High
- ENLV $4.59
- TENX $7.89
- Technical
- Relative Strength Index (RSI)
- ENLV 44.89
- TENX 49.26
- Support Level
- ENLV $0.92
- TENX $6.00
- Resistance Level
- ENLV $1.13
- TENX $6.76
- Average True Range (ATR)
- ENLV 0.10
- TENX 0.40
- MACD
- ENLV -0.01
- TENX 0.02
- Stochastic Oscillator
- ENLV 24.32
- TENX 39.47
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.